Aarti Drugs Limited has informed the Exchange regarding Appointment of Mr Mehta & Meh as Other of the company w.e.f. July 18, 2025.
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.2 pts more than Nifty Microcap 250 and 4.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Drugs informed the exchanges about its board meeting held on July 18, 2025. The board approved audited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025), with total income of Rs 52,096 lakhs, down from Rs 62,228 lakhs in the preceding quarter (Q4 FY25). The statutory auditor Gokhale & Sathe issued an unqualified clean opinion on the results. Additionally, the board appointed M/s. Mehta & Mehta, Practicing Company Secretayers, as the company's Secretarial Auditors for a five-year term spanning FY2025-26 to FY2029-30, subject to shareholder approval at the upcoming AGM. This appointment is in line with SEBI's recent amendment making secretarial audits mandatory.
Routine regulatory filing with limited stock price impact. The roughly 16% sequential drop in revenue from Q4 to Q1 is notable and worth tracking, though the YoY comparison shows modest growth. The secretarial auditor appointment is a standard compliance requirement and not material to investors.